Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 14INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 767Lymphoma 713Leukemia, Lymphocytic, Chronic, B-Cell 560Lymphoma, Follicular 515Lymphoma, Large B-Cell, Diffuse 440Precursor Cell Lymphoblastic Leukemia-Lymphoma 331Recurrence 317Lymphoma, B-Cell 294Neoplasms 261Lymphoma, Mantle-Cell 251Leukemia 231Multiple Myeloma 189Hodgkin Disease 179Leukemia, Myeloid, Acute 178Lymphoma, B-Cell, Marginal Zone 135Lymphoma, T-Cell, Peripheral 119Burkitt Lymphoma 105Myelodysplastic Syndromes 101Hematologic Neoplasms 100Lymphoma, T-Cell, Cutaneous 88Waldenstrom Macroglobulinemia 84Leukemia, B-Cell 79Lymphoma, T-Cell 74Leukemia, Myelogenous, Chronic, BCR-ABL Positive 65Lymphoproliferative Disorders 57Hematologic Diseases 57Melanoma 54Carcinoma, Non-Small-Cell Lung 54Breast Neoplasms 51Mycosis Fungoides 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Bone Marrow Failure Disorders × Lymphoid × Clear all
NCT04618081 2025-07-08

Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)

Celgene

Completed
151 enrolled
Lymphoid

Bone Marrow Failure Disorders, Lymphoma, Lymphoma, Non-Hodgkin, Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡